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ABSTRACT
U16-binding protein 4 (ULBP4), a human ligand for natural killer group 2, member 
D (NKG2D) receptor on NK cells and subsets of T cells, is thought to activate anticancer 
immune responses. However, the expression pattern and prognostic effect of ULBP4 
in nasopharyngeal carcinoma (NPC) has not been investigated. We first compared 
ULBP4 expression between archival 15 NPC tissues and 8 normal nasopharynx (NP) 
tissues using qPCR. Then ULBP4 expression among 111 NPC specimens was validated 
on immunohistochemical examination. In addition, the association of ULBP4 expression 
with clinical characteristics and survival outcomes was analyzed. Furthermore, the impact 
of ULBP4 expression in NPC cells on the cytotoxic activity of NK cells was investigated. 
Both mRNA and protein ULBP4 expressions of NPC tissues were significantly lower than 
those in normal NP tissues. However, no association of ULBP4 expression with clinical 
characteristics was observed. Patients with NPC having decreased expression of UBLP4 
had significantly poorer overall survival (OS), progression-free survival (PFS), and 
distant metastasis-free survival (DMFS) than those with preserved levels of ULBP4. On 
multivariate analyses, low expression of ULBP4 was of borderline significance for OS, PFS, 
and DMFS (P = 0.060, 0.053, and 0.076, respectively). Further, LDH analysis demonstrated 
that the cytotoxic activitity of NK cells against C666-1 or 5-8F NPC cells with lenti-ULBP4 
was considerably increased as compared to those with lenti-vector at various E/T ratios. 
Hence, restoration of ULBP4 expression may be a novel therapeutic strategy for treatment 
of NPC. However, further study is required to confirm these findings.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is regarded as 
the most common head and neck cancer in Southeast 
Asia, especially in Southern China, with the incidence 
approaching 30 per 100,000 person-years [1]. The 
current consensus on treatment includes early treatment 
with radiotherapy alone, and concurrent chemotherapy 
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combined with radiotherapy for locally advanced disease. 
Currently, the 5-year overall survival (OS) rate for 
early stage NPC can exceed 90% with use of intensity-
modulated radiotherapy (IMRT) [2]. For locally advanced 
NPC, OS rates of 78.4%-80% have been reported with a 
combination of IMRT and chemotherapy [3, 4]. However, 
20%~30% of patients with NPC develop treatment failure 
and distant metastasis [5, 6]. It is therefore necessary to 
explore novel therapeutic modalities to treat patients with 
NPC.
The role of immunotherapy in human cancers 
has attracted much attention. Natural killer (NK) cells 
and CD8+ T cells represent effector immune cells that 
detect and eliminate transformed tumor cells by innate 
and adaptive immunity, respectively [7]. The NK group 
2, member D (NKG2D) serves as an activating immune 
receptor expressed on the surface of a vast majority of NK 
cells, CD8+ T cells, γδ T cells, and in certain subsets of 
CD4+ T cells [8], NKG2D could trigger cytotoxic activity 
of immune effector lymphocytes after binding to its 
distinct ligands, which consist of the MHC class I-related 
chain (MIC) family (MICA and MICB) and the UL16 
binding protein or retinoic acid early transcript (ULBP/
RAET) family (ULBP1-6) expressed on the surface of 
tumor cells. This is a key mechanism leading to the killing 
of infected and transformed tumor cells by NK and T cells 
[9, 10].
Stress-induced ULBP4 (RAET1E), a 
transmembrane molecule belonging to the ULBP family, 
has been described as a human ligand of NKG2D. It is 
known to be up-regulated on the surface of virus- or 
bacteria- infected cells [11, 12], and in several transformed 
tumor cells in ovarian, cervical, colon and liver cancers 
[12-14]. However, its expression in normal tissues is 
largely restricted, including skin and small intestine [11, 
15]. ULBP4-NKG2D interaction can not only activate 
NK cell and NK-mediated cytotoxicity [11, 15, 16], but 
also serve to stimulate the cytotoxicity of CD8+ T cell 
[11], which suggests an influence of ULBP4 on both 
innate and adaptive immune responses. In addition, 
ULBP4 expression on Epstein-Barr virus (EBV)-infected 
peripheral blood cells was shown to enhance the cytotoxic 
effect of γδ T cell on tumor cells and EBV-infected B 
cells by binding to both TCRγδ and NKG2D [12]. This 
hints at the importance of ULBP4 in the elimination of 
EBV infection. The ubiqutious association between 
NPC and EBV infection is well-documented [17]. Thus, 
the expression level of ULBP4 on NPC cell surface 
may determine its antitumor efficacy, besides being of 
prognositic value in patients with NPC.
Currently, the tumor specific expression pattern of 
ULBP4 and its association with clinical outcomes has 
been reported for human colorectal, ovarian, breast, and 
cervical cancers [14, 18-20]. However, the expression 
status and clinical significance of ULBP4 in patients wtih 
NPC has not been investigated. In the present study, we 
retrospectively analyzed the expression pattern of ULBP4 
in NPC specimens at the mRNA and protein levels prior 
to initiation of treatment, and assessed its prognostic 
relevance. In addition, the impact of ULBP4 expression in 
NPC cells on the cytotoxic activity of NK cells was also 
investigated in vitro.
RESULTS
Characteristics and treatment outcomes
Of the 111 NPC patients, 81 (73.0%) were males 
and 30 (27.0%) were females; the median age of patients 
was 48 years (range, 12 to 82 years). Histologically, 106 
(95.5%) of the patients had WHO type III disease and 5 
(4.5%) had WHO type II disease. According to the current 
7th UICC/AJCC staging system, 3 (2.7%), 35 (31.5%), 
45 (40.5%), and 28 (25.2%) patients out of the total 111 
NPC patients were categorized as stages I, II, III, and IV, 
respectively. Information on other variables including 
T classification, N classification, and chemotherapy is 
shown in Table 1. For the entire group, the 5-year OS, 
PFS, DMFS, and LRFS rates were 86.4%, 83.5%, 84.4%, 
and 95.2%, respectively. 6 patients were found to develop 
disease recurrence, of which 5 patients developed local 
relapse, 2 patients experienced regional relapse, and 1 
patient had both local and regional relapse. In addition, 16 
patients were found to develop distant metastasis. Finally, 
a total of 15 patients died: 9 of distant metastasis, 1 of 
local relapse, 1 of treatment complications, 3 of other 
medical conditions, and 1 of unknown reason.
ULBP4 was transcriptionally downregulated in 
NPC by qPCR
In order to determine the transcript expression levels 
of ULBP4, we analyzed the differences between 15 NPC 
and 8 normal NP fresh frozen tissue specimens by qPCR. 
It was found that the ULBP4 mRNA levels of NPC tissue 
specimens were significantly decreased as compared to 
that of normal NP tissue specimens (P = 0.001), as shown 
in Figure 1.
ULBP4 expression was significantly 
downregulated in NPC at protein level on IHC
On immunohistochemical analyses, 75 out of 
the 111 tumor samples had both tumor and normal 
epithelial tissues on the same slide. Therefore, ULBP4 
expression levels were scored in both cancer tissues and 
the adjacent non-cancerous tissues. ULBP4 expression 
was lower in most cancer tissues when compared to 
the adjacent normal nasopharyngeal epithelial tissues 
(Figure 2). The IHC staining score 0-7 (≤ mean score of 
adjacent normal epithelial tissues) indicated low and the 
score 8-12 (> mean score of adjacent normal epithelial 
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Table 1: Associations between ULBP4 expression and clinical characteristics of patients with nasopharyngeal 
carcinoma




Total 111 79 32
Gender 2.5 0.114
 Male 81 61 20
 Female 30 18 12
Age 0.087 0.768
 ≤48 years 60 42 18
 >48 years 51 37 14
Histology 2.479 0.114
 WHO II 5 2 3
 WHO III 106 77 29
T classification 0.355 0.551
 T1-2 50 37 13
 T3-4 61 42 19
N classification 0.60 0.806
 N0-1 85 60 25
 N2-3 26 19 7
AJCC stage 0.178 0.673
 I-II 38 28 10
 III-IVa+b 73 51 22
Chemotherapy 0.237 0.626
 No 13 10 3
 Yes 92 69 29
Abbreviation:WHO: World Health Organization.
Figure 1: ULBP4 expression was decreased in NPC at mRNA level. The mRNA expression of ULBP4 was significantly 
downregulated in 15 NPC tissue specimens as compared to that in 8 normal nasopharynx (NP) tissue specimens.
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tissues) indicated high expression. Among these 75 tumor 
specimens, a high expression of ULBP4 in the adjacent 
normal nasopharyngeal epithelial tissues was found in 
68% (51/75), whereas the expression in the corresponding 
cancer tissues was only in 26.7% (20/75) (χ2 = 25.7, 
P < 0.001) (Table 2). Overall, only 32 out of the 111 
cancerous specimens had a high ULBP4 expression. 
These observations indicated the heterogeneity existing in 
the expression of ULBP4 of NPC tissues; however, the 
expression in NPC tissues was significantly lower in NPC 
tissues than that in the adjacent normal epithelial tissues.
Association between expression of ULBP4 and 
clinical characteristics
To investigate whether the different expression of 
ULBP4 in NPC was significantly associated with clinical 
characteristics, all paraffin-embedded specimens were 
categorized based on different clinical characteristics. 
However, no significant association was found between 
ULBP4 expression and gender, age, pathologic type, T 
classification, N classification, clinical stage, and use of 
chemotherapy (Table 1).
Association between expression of ULBP4 and 
clinical outcomes
To explore if the correlation between the differential 
expression of ULPB4 in NPC and the clinical outcomes, 
we made a comparison of survival outcomes, including 
5-year OS, DFS, LRFS, and DMFS rates, between 
NPC patients with low and high ULBP4 expression, by 
univariate log-rank survival analysis. NPC patients with 
high ULBP4 expression had better 5-year OS, DFS, 
Figure 2: ULBP4 expression in adjacent normal epithelia and carcinoma cells as evaluated by immunohistochemistry 
analyses. A. High ULBP4 expression was shown in adjacent normal naospharyngeal epithelia and low ULBP4 expression was shown in 
carcinoma cells (original magnificaiton ×100). B. High ULBP4 expression was shown in adjacent normal naospharyngeal epithelia and low 
ULBP4 expression was shown in carcinoma cells (original magnificaiton ×200). C. Positive control: ULBP4 expression was detected in 
human ovarian cancer tissue under the same conditions with anti-ULBP4 antibody (original magnificaiton ×200). D. Negtive control: NPC 
tissue was stained under the same conditions but anti-ULBP4 antibody was not used (original magnificaiton ×200).
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and DMFS rates compared to those with low ULBP4 
expression (P = 0.044, 0.012, and 0.026, respectively) 
(Figure 3A, 3B, and 3D). However, ULBP4 expression 
in NPC had no statistically significant association with 
5-year LRFS rates (Figure 3C). These results suggested 
that ULBP4 expression was negatively associated with 
tumor progression and distant metastasis. Additionally, 
other potential prognostic factors, such as gender, age, 
T classification, N classification, clinical stage, and use 
of chemotherapy, were also included to assess their 
correlation with clinical outcomes (Table 3). It was found 
that N classification correlated with both 5-year OS and 
DMFS rates, and females had a better 5-year DFS and 
DMFS rates than males.
Low ULBP4 expression may be an independent 
predictor of poor prognosis
To further explore whether expression of ULBP4 
has independent prognostic value in patients with NPC, 




Low expression High expression
Carcinoma cells 55(73.3%) 20(26.7%)
25.7 <0.001
Adjacent epithelia 24(32%) 51(68%)
Figure 3: Low ULBP4 expression predicts inferior survival outcomes in patients with NPC. The survival data was 
calculated and plotted by the Kaplan-Meier method. Patients were determined as low or high ULBP4 expression based on ULBP4 
immunohistochemistry. *P < 0.05. A. Overall survival (OS). B. Progression-free survival (PFS). C. Local relapse-free survival (LRFS). D. 
Distant metastasis-free survival (DMFS).
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multivariate Cox regression analysis was performed 
to avoid the interference among various prognostic 
factors. The following variables were adjusted in the Cox 
proportion hazards model by the backward elimination 
method: ULBP4 expression (low expression vs. high 
expression), age, sex (male vs. female), T classification 
(T1-2 vs. T3-4), N classification (N0-1 vs. N2-3), use 
of chemotherapy (no vs. yes). As shown in Table 4, N 
classification was found to affect both OS and DMFS 
(P =0.004 for OS and P =0.048 for DMFS). However, 
ULBP4 expression level was not significantly associatied 
with death or any type of treatment failure. Of note, 
low ULPB4 expression was found to have a borderline 
significance for death, disease failure, and distant 
failure (P = 0.060, 0.053, 0.076, respectively). These 
findings indicated that low ULBP4 expression may be an 
independent prognostic factor.
Impact of ULBP4 expression on the cytotoxicity 
activity of NK cells in vitro
Due to low ULBP4 expression in NPC tissues, 
two NPC cell lines (C666-1, 5-8F) with relatively 
lower ULBP4 expression were determined to do further 
functional validation in vitro (Figure 4A and 4B). To 
investigate the effect of the ectopic ULBP4 expression 
on the cytotoxic activtity of NK cells, C666-1 and 5-8F 
cells were both infected with lentiviral particles carrying 
ULBP4 or its empty vector. Figure 4C and 4D showed 
a higher expression levels of ULPB4 after infection of 
ULBP4 in both C666-1 and 5-8F cells as compared to than 
in controls. In the LDH cytotoxicity analysis, the cytotoxic 
activitity of NK cells against NPC cell lines (C666-1 or 
5-8F) with lenti-ULBP4 was significantly increased as 
compared to those with lenti-vector at the three E/T ratios 
Table 3: Potential prognostic factors by univariate log-rank analysis for patients with nasopharyngeal carcinoma
Factors
OS PFS LRFS DMFS
Events P* Events P* Events P* Events P*
ULBP4 expression 0.044* 0.012* 0.132 0.026*
 Low (n=79) 14 18 5 15
 High (n=32) 1 1 0 1
Gender 0.064 0.004* 0.155 0.010*
 Male (n=81) 14 19 5 16
 Female (n=30) 1 0 0 0
Age 0.905 0.458 0.492 0.651
 ≤48 (n=60) 8 9 2 8
 >48 (n=51) 7 10 3 8
T classification 0.133 0.923 0.239 0.756
 T1-2 (n=50) 4 9 1 8
 T3-4 (n=61) 11 10 4 8
N classification 0.012* 0.070 0.986 0.018*
 N0-1 (n=85) 8 12 4 9
 N2-3 (n=26) 7 7 1 7
AJCC stage 0.066 0.316 0.089 0.319
 I-II (n=38) 2 5 0 4
 III-IVa+b (n=73) 13 14 5 12
Chemotherapy 0.789 0.362 0.423 0.490
 No (n=13) 2 1 0 1
 Yes (n=92) 13 18 5 15
Notes:*P < 0.05 indicates statistically significance among the variables. Events represent the numbers of failed cases for 
OS, PFS, LRFS, DMFS, respectively.
Abbreviations:OS: overall survival; PFS: progression-free survival; LRFS: local relapse-free survival; DMFS: distant 
metastasis-free survival.
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Table 4: Independent prognostic factors by multivariate cox-regression analysis for patients with nasopharyngeal 
carcinoma
Endpoint Factors P* HR 95%CI for HR
Death N classification 0.004* 4.832 1.674-13.946
ULBP4 expression 0.060 0.142 0.018-1.087
Age 0.022 1.045 1.006-1.086
Disease failure N classification 0.098 2.241 0.854-5.883
ULBP4 expression 0.053 0.132 0.017-1.026
Distant failure N classification 0.048* 2.808 1.010-7.807
ULBP4 expression 0.076 0.154 0.020-1.218
Notes: *P < 0.05 indicates statistically significance among the variables.
Abbreviations: HR: hazard ratio; CI: confidence interval.
Figure 4: Impact of ULBP4 expression on the cytotoxic activity of NK cells in vitro. A. qPCR analysis of ULBP4 expression 
levels among four NPC cell lines. B. Western blotting analysis of ULBP4 expression levels among four NPC cell lines. C. qPCR analysis 
of ULBP4 expression levels in C666-1 or 5-8F cells with lenti-ULBP4 compared with those with lenti-vector. D. Western blotting analysis 
of ULBP4 expression levels in C666-1 or 5-8F cells with lenti-ULBP4 compared with those with lenti-vector. E. LDH analysis of the 
cytotoxic activitity of NK cells against C666-1 with lenti-ULBP4 compared with that with lenti-vector at E/T ratios of 10:1, 20:1, and 40:1, 
respectively (*P < 0.05). F. LDH analysis of the cytotoxic activitity of NK cells against 5-8F with lenti-ULBP4 compared with that with 
lenti-vector at E/T ratios of 10:1, 20:1, and 40:1, respectively (* P<0.05).
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(10:1, 20:1, and 40:1), respectively (all P <0.05, Figure 
4E and 4F).
DISCUSSION
The advent of IMRT combined with other new 
therapies has improved clinical outcomes in patients 
with NPC. Nevertheless, some cases tend to develop 
tumor progression and distant metastasis with the current 
treatment modalities. Though the TNM staging system for 
NPC is generally considered to be the gold standard to 
guide treatment and predict prognosis [21, 22], it may not 
be enough to provide optimal risk-stratification. Therefore, 
identification of additional prognostic biomarkers 
is required for guiding the individualized treatment. 
To our knowledge, this is the first study to explore the 
pattern of ULBP4 expression and its prognostic value in 
patients with NPC. In this study, ULBP4 was found to 
be significantly downregulated in primary NPC tissues 
when compared with normal NP tissues at both mRNA 
and protein levels. More importantly, low expression of 
ULBP4 was demonstrated to be of borderline significance 
in relation to death, disease failure and distant metastasis. 
Furthermore, low expression of ULBP4 in NPC cell 
lines attenuated the cytotoxic effect of NK cells in vitro, 
which was validated on LDH cytotoxicity analysis. These 
findings suggest that ULBP4 may prove to be a useful 
prognositc factor and a novel therapeutic target for NPC.
As a stress-inducible NKG2D ligand, ULBP4 is 
expressed in a variety of epithelial tumor cells, but is 
poorly expressed in normal non-tumor tissues [12-16, 18-
20]. Conversely, our present study showed that ULBP4 
was expressed at high levels in normal NP tissues rather 
than that in NPC tissues (Table 2, Figures 1 and 2). NPC 
is characterized by concomitant chronic inflammation, 
with the inflammatory cells releasing inflammatory 
factors such as IL-6 in NPC tissues, which promotes the 
development and progression of NPC [23, 24]. Under such 
conditions of stress, adjacent normal epithelial cells may 
also be stimulated by chronic inflammation to express 
high expression levels of ULBP4. Likewise, ULBP4 was 
found to be highly expressed on 8 normal fresh frozen NP 
tissues obtained from healthy individuals with chronic 
nasopharyngeal mucositis likely because of chronic 
inflammation stimulus. As high expression of ULBP4 
on the surface of cells makes them more susceptible to 
be detected and killed by NK and T cells, it may prevent 
the transformation of adjacent normal epithelial cells into 
cancerous cells. In the present study, however, expression 
of ULBP4 in NPC cells was markedly decreased, which 
suggested that the down-regulation of ULBP4 may be one 
of the factors contributing to the immune evasion of NPC. 
Two possible mechanisms may explain the decreased 
surface expression of ULBP4 on NPC cells. Firstly, the 
ULBP4 expressed on the surface of tumor cells has been 
reported to be proteolytically cleaved by metalloproteases 
(MMPs) [25]. Such shedding could lead to downregulation 
of both the surface expression of ULBP4 on tumor cells 
and the expression of NKG2D receptor on effector cells, 
thus impairing NK cell cytotoxicity and T cell activation. 
Secondly, transforming growth factor-β (TGF-β), a tumor 
cytokine, has been reported to selectively suppress the 
transcription and protein expression of MICA, ULBP2 and 
ULBP4 on malignant glioma cells [26]. In addition, TGF-β 
may decrease the expression of NKG2D receptor on NK 
cells and T cells [27]. Secretion of TGF-β by NPC cells is 
well-documented and is known to promote the progression 
and metastasis of NPC [28, 29], herein ULBP4 expression 
may be also downregulated by TGF-β on NPC cells. 
However, definitive evidence of the specific underlying 
mechanisms involved in the negative regulation of ULBP4 
expression in NPC tissues is still lacking.
Considering the heterogeneous expression of 
ULBP4 in primary NPC (Figure 5), we assessed the 
correlation between the deceased expression of ULBP4 
and various clinicopathological characteristics. However, 
we found no significant association between the two 
(Table 1). These findings hinted that ULBP4 may serve 
as a novel biomarker independent of other clinical 
parameters. Moreover, the essential clinical parameters 
were comparable between the NPC patients with high 
and low expression of ULBP4, which allowed for a better 
comparison of the prognostic value between NPC patients 
with differential expression levels of ULBP4.
In spite of the heterogeneity in the surface 
expression of ULBP4 on NPC cells, univariate survival 
analysis showed that NPC patients with high expression of 
ULBP4 had better OS, PFS, and DMFS rates as compared 
to those associated with low expression of ULBP4 (Figure 
3). These results indicated that the high expression of 
ULBP4 may serve to enhance host immune responses 
against NPC, thereby improving the prognosis in patients 
with NPC. This is in line with the theory that the high 
expression of NKG2D ligands may promote tumor 
immune surveillance by uniquely binding to the NKG2D 
receptor, and inducing the killing of cancer cells by NK 
cells and a subgroup of T cells [30]. Hence, expression 
levels of ULBP4 may serve as a criterion to identify 
patients with NPC at increased risk of tumor progression 
and distant metastasis. However, some reports found no 
evidence of the predictive effect of ULBP4 in colorectal 
cancer and early breast cancer [18, 20]. Furthermore, an 
inverse association of ULBP4 expression with the disease-
free survival in cervical cancer and disease-specific 
survival in ovarian cancer has been reported [14, 19]. 
This could be explained by the overexpression of NKG2D 
ligands which may bring about an overstimulation effect, 
leading to insensitivity and anergy of NK and T cells, 
which in turn may contribute tumor immune evasion or 
immunoediting to some extent [30]. Taken together, these 
results hinted at diverse effects of ULBP4 in modulating 
anticancer immune responses depending on the type of 
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cancer and the corresponding tissue microenvironment, 
which deserves to be investigated further.
On multivariate analysis, low ULBP4 expression 
was no longer associated with adverse OS, DFS, and 
DMFS rates in patients with NPC. Nevertheless, a 
borderline association with death (P = 0.060), disease 
failure (P = 0.053), and distant failure (P = 0.076) 
was observed (Table 4). This could be related to a 
favorable prognosis gained from IMRT and combined 
chemotherapy, which necessitates the enrollment of a 
larger number of patients with NPC to demonstrate the 
independent prognostic value of expression of ULBP4 
in patients with NPC. ULBP4 may also prove to be an 
attractive target for developing an alternative therapy 
for NPC. Therapeutic strategies that reduce or block 
the proteolytic cleavage of soluble NKG2D ligands, 
for example, by inhibiting MMP activity to reduce the 
shedding of NKG2D ligands, may restore the expression 
of NKG2D receptor on immune effector cells and enhance 
their anticancer cytotoxicity [31]. In addition, reduction 
in tumor-induced immunosuppressive molecules such 
as TGF-β would increase the expression of NKG2D 
ligands on tumor cells, thereby improving the cytotoxic 
ability of NK cells and CD8+ T cells [32]. Therefore, 
future combined treatments using conventional cancer 
therapies and novel immunotherapies, towards enhancing 
the expression of ULBP4, may provide new therapeutic 
avenues in the prevention of tumor progression and distant 
metastasis in patients with NPC.
To further verify the impact of ULBP4 expression 
on the cytotoxicity activity of immune cells in vitro, our 
LDH cytotoxicity analysis demonstrated considerably 
increased the cytotoxic activity of NK cells against NPC 
cell lines (C666-1 or 5-8F) with lenti-ULBP4 as compared 
to those with lenti-vector at the three E/T ratios (10:1, 
20:1, and 40:1), respectively (Figure 4). These results 
were consistent with previous studies that high ULBP4 
expression could stimulate NK cell and NK-mediated 
cytotoxicity in vitro [11, 15, 16], which suggested 
that restoration of ULBP4 expression may be a novel 
Figure 5: Criteria for ULBP4 staining intensity score. A. Intenstiy score: 0. B. Intensity score: 1. C. Intensity score: 2. D. Intensity 
score: 3. The micrograghs were obtained and processed under the same conditions (original magnificaiton ×200).
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therapeutic strategy for treatment of NPC. However, the 
impact of ULBP4 expression on cytoxicity of CD8+T 
or other T cells in NPC cell lines needs to be further 
investigated.
One of the limitations was that our current study 
was performed by retrospective analyses, and the number 
of our enrolled NPC patients seemed to be inadequate. 
In addition, concurrent chemoradiotherapay is still 
considered to be the standard therapeutic method for 
locally advanced NPC, even in the IMRT era. However, 
much heterogeneity with respect to the chemotherapy 
regimens existed in our study; only 58.1% patients 
received concurrent-based chemotherapy, which was 
due to participation of patients in the randomized clinical 
trials of certain chemotherapy regimens, or probably at 
the discretion of attending physicians in individual cases. 
Consequently, a prospective, randomized, and controlled 
clinical study with larger sample size is required to further 
resolve these issues.
To conclude, our study, perhaps for the first time, 
demonstrated decreased expression levels of ULBP4 in 
NPC tissues as compared to that in normal NP epithelial 
tissues. In addition, low ULBP4 expression correlated 
with poor OS, DFS, DMFS, and may prove to be a novel 
prognostic factor. Low ULBP4 expression in NPC cell 
lines could attenuate the cytotoxicity of NK cells in 
vitro. Restoration of ULBP4 expression may be a novel 




The study was conducted on a series of 111 formalin-
fixed, paraffin-embedded samples obtained from patients 
with newly diagnosed and histologically proven cases of 
NPC, but without distant metastasis, in Fujian Provincial 
Cancer Hospital, between January and December 2010. 
All NPC specimens were obtained prior to initiation of 
chemotherapy or radiotherapy. All patients underwent 
MRI scan of the nasopharynx and neck; the pretreatment 
evaluation was based on the institutional protocol [5]. 
All patients had a satisfactory Karnofsky performance 
status score (> 70). The study exclusion criteria included 
a prior or synchronous malignancy. Disease staging was 
performed according to the 7th edition of the International 
Union Against Cancer/American Joint Committee on 
Cancer (UICC/AJCC) staging system for NPC [21, 22]. 
An additional fresh frozen samples (15 primary NPC 
tissues from NPC patients and 8 nasopharynx (NP) tissues 
from healthy individuals with chronic nasopharyngeal 
mucositis) archived in 2012 were also obtained from our 
hospital. All procedures were conducted after obtaining 
due approval of the Institutional Review Board at the 
Fujian Provincial Cancer Hospital, China (reference 
number 2015-010-02).
Cell line and cell culture
The human cell lines CNE-1, CNE-2, 5-8F, and 
C666.1 were all maintained in RPMI 1640 medium 
(Gibco, Grand Island, NY, USA) supplemented with 
10% fetal bovine serum (Gibco, Australia). Peripheral 
blood mononuclear cells (PBMCs) were isolated from 
the whole blood of healthy individuals by Ficoll density 
gradient centrifugation, then NK cells were cultured in 
lymphocyte serum-free medium KBM 581 (Corning, 
NY, USA) and were amplified by a combination of IL-2 
(500IU/mL), IL-12 (2 ug/mL), IL-15 (2 ug/mL), and IL-
18 (10 ug/mL) every other day for a total of 14-17 days. 
Ultimately, highly pure NK cells were isolated by CD56 
MicroBeads (Miltenyi Biotec Inc, Auburn, CA, USA) with 
VarioMACS system. The purity CD3-/CD56+ NK cells 
was assessed to be 90%-95% on flow cytemerty.
RNA extraction and quantitative real-time PCR 
(qPCR)
Total RNA from 15 NPC, 8 normal NP tissue 
specimens and NPC cell lines was extracted by TRIzol 
reagent (Invitrogen), and reversely transcribed with 
the PrimeScript RT reagent kit (TaKaRa, Japan). 
qPCR was performed on a LightCycler Roche 
480 using DyNAmo Flash SYBR-Green qPCR kit 
(Thermo Fisher Scientific, USA) according to the 
manufacturer’s standard manual. Primer sequences used 
for ULBP4 detection were as follows: forward primer: 
5’-CGCCTTCTTTTGTTTCTGCTG-3’, reverse primer: 
5’-CCTGAGGTCTCGCCCCACT-3’. β-actin was used as 
the internal control, and its primer sequences were set as 
follows: forward: 5’-TGACGTGGACATCCGCAAAG-3’, 
reverse: 5’-CTGGAAGGTGGACAGCGAGG-3’. 
Relative quantification of mRNA expression was 
performed by the comparative 2-ΔΔct method to calculate 
the difference between amplifications of ULBP4 and 
β-actin RNA. The experiments were performed with 
three technical replicates, and the mean fold changes and 
standard deviation were also calculated.
Immunohistochemical study
Expression of ULBP4 in NPC tissue samples was 
assessed on immunohistochemistry (IHC) examination. 
Paraffin-embedded NPC specimens were sliced into 4-μm 
thick sections, deparaffinised in xylene and rehydrated 
through a graded ethanol series. Next, the slides were 
boiled in a pressure cooker until gas discharging for 2.5 
min in citrate buffer (Maixin-bioMVS-0101) (pH 6.0). 
Endogenous peroxidase was blocked by treatment with 
3% hydrogen peroxide (H2O2) for 10 min. Subsequently, 
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sections were incubated with mouse anti-human ULBP4 
monoclonal antibody (1:1000, R&D Systems, Inc., 
Minneapolis, MN, USA) for 1h at 37°C; positive and 
negative controls were also used. After washing with 
phosphate-buffered saline (PBS) 3 times, tissues were 
incubated with horseradish peroxidase-conjugated anti-
mouse Ig polymer as a second antibody (Elivision kit, 
Maixin-Bio, Fuzhou, People’s Republic of China) for 
30 min at 37°C. Finally, sections were visualized using 
diaminobenzidine (DAB) staining kit, counter-stained 
with hematoxylin, and observed under the microscope.
Evaluation of IHC staining
To determine the expression of ULBP4, all slides 
were stained under the same conditions using a standard 
protocol. ULBP4 is primarily expressed on membrane of 
epithelial cells, but seldom shows a cytoplasmic pattern. 
The expression levels of ULBP4 were assessed by two 
scores, i.e., the staining intensity and the percentage of 
the stained epithelial cells. Considering that the staining of 
tumors was relatively heterogeneous, the immunoreactive 
scores of ULPB4 expression were determined as 
previously described [14]. Briefly, the staining intensity 
was scored as negative (0), weak (1), moderate (2), or 
strong staining (3) (as shown in Figure 5). The percentage 
of positive staining was scored as 0% (0), < 25% (1), 
25%-50% (2), 50.1%-75% (3), or > 75% (4). The overall 
score was calculated by multiplying intensity score and 
percentage score, which ranged from 0 to 12. All slides 
were evaluated by two independent pathologists in a 
double-blinded manner. Any slides with conflicting scores 
were resolved by consensus.
Western blotting
Western blotting analyses were conducted with the 
standard protocols. In brief, human NPC cell lines were 
lysed in modified lysis buffer (Roche) for 15 minutes on 
ice. The BCA Protein Assay kit (Pierce, USA) was used 
to determine cellular protein concentration. Then total 
protein from cells was extracted by loading buffer (0.2% 
bromophenol blue, 20% glycerol, 125 mM Tris-HCl, 640 
mM βME, 4% SDS), and boiled for 10 minutes. After that, 
total proteins were separated on 10% SDS-PAGE gels 
and electro-transferred to membranes (Millipore). Then 
the membranes were probed with rabbit polyclonal anti-
ULBP4 antibody (1:500; Abcam, Chicago, IL, USA) at 
4 °C overnight, and then with anti-rabbit IgG secondary 
antibody (1:5000; Sigma, St. Louis, MO, USA). β-actin 
was used as protein loading controls.
Plasmid construction and lentivirus transduction
To obtain NPC cell lines to overexpress ULBP4, 
the sequence of ULBP4 was cloned into the pLVTHM 
lentiviral vector, and the recombinant plasmid 
was renamed as lv-ULBP4. The lentiviral viruses 
overexpressing ULBP4 (lenti-ULBP4) and the nagative 
control lenti-vector (lenti-vector) were purchased from 
Life-Int (Xiamen, China). These were used to infect C666-
1 and 5-8F NPC cell lines according to the manufacturer’s 
recommended protocol. All cell qPCR, Western blotting, 
and functional studies were performed at least 72 hours 
after lentiviral infection.
Cytotoxicity assay
Lactate dehydrogenase (LDH) assay was performed 
to reflect the cytotoxic activity of effector cells on 
target cells using a nonradioactive cytotoxicity assay kit 
(Promega, Madison, WI, USA). Generally, the target cells 
(C666-1, 5-8F), with lenti-vector or lenti-ULBP4, were 
set in triplicate in 96-well culture plates and incubated 
with the effector cells (NK cells) with an effector to target 
(E/T) ratio of 10:1, 20:1 or 40:1. Maximal release of LDH 
was conducted by complete lysis of target cells. Target 
cells without effector cells were considered as negative 
controls (spontaneous release). The cytotoxic effect was 
measured as follows: percentage cytotoxicity (%) = 
[(experimental release - spontaneous release of effector 
cells - spontaneous release of target cells) / (maximal 
release of target cells - spontaneous release of target cells)] 
x100.
Treatment
All 111 patients were initially treated with 
definitive IMRT. The details of the IMRT have been 
previously described [5]. Of the 108 NPC patients with 
Stages II-IVB disease, 98 (90.7%) received platinum-
based chemotherapy. The sequence administered was 
induction in 10 (10.2%), concurrent in 11 (11.2%), 
concurrent-adjuvant in 5 (5.1%), induction-concurrent 
in 19 (19.4%), induction-adjuvant in 31 (31.6%), and 
induction-concurrent-adjuvant in 22 (22.4%) patients. 
Whenever possible, salvage treatment with transcavitary 
brachytherapy, surgery, and chemotherapy were 
administered in case of recurrence or disease persistence.
Follow-up and statistical analyses
The duration of follow up was calculated from 
the date of diagnosis to death or to the last follow up 
examination for those still alive. Generally, after the 
completion of therapy, patients were followed up every 3 
months during the first 2 years, every 6 months from year 
2 to year 5, and annually thereafter. The median follow-
up time for the whole group was 66 months (range, 7-74 
months). Overall survival (OS), progression-free survival 
(PFS), local relapse-free survival (LRFS), and distant 
metastasis-free survival (DMFS) was calculated from the 
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initial diagnosis to death, disease failure, local failure, or 
distant failure. For patients who were still alive at the last 
follow up, the duration of survival was censored.
All statistical analyses were performed using the 
version 17.0 of Statistical Package for the Social Science 
software (SPSS, Inc, Chicago, IL, USA). t test was 
employed to compare mRNA expressions of ULBP4 in 
the tumor and non-tumor tissue specimens, and to compare 
the cytotoxic activity of NK cells against NPC cell lines 
with lenti-ULBP4 and lenti-vector. Chi-squared test was 
used to compare the ULBP4 expression in cancer cells 
with that in adjacent normal nasopharyngeal epithelia, 
and to evaluate the association between the expression of 
ULBP4 and clinicopathological characteristics. Survival 
rates were calculated by the Kaplan-Meier method and the 
statistical significance of differences were assessed by log-
rank test. Multivariate analyses using the Cox proportional 
hazards model were conducted to explore the independent 
prognostic factors for the whole cohort. In all cases, a 
two-tailed P value of <0.05 was considered statistically 
significant.
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